Definium reported positive top-line results from its Phase 3 Emerge trial of DT-120 (lysergide) in major depressive disorder, using a single dose delivered as an orally disintegrating tablet (100 µg). The company said the therapy significantly improved symptoms on the Montgomery–Åsberg Depression Rating Scale (MADRS) versus placebo. At six weeks, Definium reported a 13.3-point MADRS decline in the DT-120 group compared with a 5.2-point decline in placebo. By 12 weeks, the effect moderated but remained higher than placebo, with an 11.0-point decrease from baseline versus 3.6 points for patients receiving placebo. The announcement adds to the late-stage development momentum for psychedelics in psychiatry, where Phase 3 outcomes will determine whether regulatory pathways can support broader use beyond earlier studies. Definium said the results bring DT-120 closer to potential approval, with additional trial detail expected as the program matures. For biotech investors, the key near-term catalyst is how durable the signal is across follow-up periods and whether subgroup analyses show consistent benefit over placebo while maintaining an acceptable safety profile.